Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: December 3rd, 2010 - December 3rd, 2011

Target Audience
This activity was developed for hematologists and medical oncologists, as well as nurses, pharmacists, and other allied health professionals who are interested in meeting the challenges faced when treating patients with multiple myeloma (MM) in academic and community settings.

Learning Objectives
At the completion of this activity participants should be able to:

  • Demonstrate the ability to diagnostically differentiate symptomatic multiple myeloma (MM) from other plasma cell disorders.
  • Apply knowledge of the etiology and natural progression of MM to guide decisions regarding the timing and selection of therapeutic interventions.
  • Evaluate novel therapeutic regimens as induction therapy for patients with MM considering a stem cell transplant in order to provide the most rapid response and allow the largest amount of stem cell collection while maintaining safety and tolerance.
  • Discuss the emerging role of maintenance therapy in the treatment of patients with MM based on data from recent clinical trials.
  • Explain how individual- and disease-related factors (eg, age, performance status, comorbidities, patient preferences, cytogenetic abnormalities) impact choice of therapeutic agents and management strategies for patients with MM.
  • Integrate evidence-based supportive care measures that minimize bone complications and treatment-related toxicities into management strategies for patients with MM receiving novel agents.

Estimated time to complete activity: 2 hours

Physician Accreditation
The University of Cincinnati designates this activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 2 contact hours.

Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 2 contact hours (0.2 CEUs) of continuing education credit. The universal program number for this activity is 0468-9999-10-070-H01-P.

Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Content may include non-FDA-approved uses.

Shoba Kankipati, MD has served as a faculty presenter for Millennium.

Jonathan L. Kaufman, MD is a Consultant for Celgene, Millennium, and Onyx, and is on the research review committee for Keryx.

Hakan Kaya, MD, has received honoraria from Alexion, Celgene, Genzyme, and Genentech, and is on the speaker's bureau for Millennium.

Noopur Raje, MD, is a consultant for Amgen, Celgene, and Novartis.

G. David Roodman, MD, PhD, is a consultant for Acceleron Pharma, Amgen, Celgene, Millennium, and Novartis, and has received research and grant support from Novartis.

Leon Dragon, MD, FACP, and Ari Umutyan, MD, have nothing to disclose.

The associates of the University of Cincinnati, Medical Learning Institute, Inc., the accredited providers for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Related Items
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Emerging Treatments and Evolving Strategies for the Cost Effective Management of Multiple Myeloma
Jonathan L. Kaufman, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Payer Perspective ASH 2011 Update: Multiple Myeloma Treatment Trends and Strategies for Value-Based Care
Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA
Supplements published on March 5, 2012
Considerations in Multiple Myeloma Ask the Experts: Newly Diagnosed Patients
Jonathan L. Kaufman, MD , Charise Gleason, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
Supplements published on March 31, 2011
New Treatments for Optimizing Bone Health in Patients With Multiple Myeloma: Proceedings From the Symposium Held at the IX International Meeting on Cancer-Induced Bone Disease
G. David Roodman, MD, PhD, John D. Shaughnessy, Jr, PhD, Noopur Raje, MD
Supplements published on February 11, 2010
Last modified: March 21, 2014